FR2965178B1 - Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer - Google Patents
Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimerInfo
- Publication number
- FR2965178B1 FR2965178B1 FR1003859A FR1003859A FR2965178B1 FR 2965178 B1 FR2965178 B1 FR 2965178B1 FR 1003859 A FR1003859 A FR 1003859A FR 1003859 A FR1003859 A FR 1003859A FR 2965178 B1 FR2965178 B1 FR 2965178B1
- Authority
- FR
- France
- Prior art keywords
- alzheimer
- disease
- treatment
- pharmaceutical composition
- composition used
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1003859A FR2965178B1 (fr) | 2010-09-29 | 2010-09-29 | Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer |
PCT/FR2011/000528 WO2012042128A1 (fr) | 2010-09-29 | 2011-09-27 | Composition pharmaceutique comprenant de la memantine et de la vitamine d pour le traitement de la maladie d 1 alzheimer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1003859A FR2965178B1 (fr) | 2010-09-29 | 2010-09-29 | Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2965178A1 FR2965178A1 (fr) | 2012-03-30 |
FR2965178B1 true FR2965178B1 (fr) | 2012-10-05 |
Family
ID=43304969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1003859A Active FR2965178B1 (fr) | 2010-09-29 | 2010-09-29 | Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR2965178B1 (fr) |
WO (1) | WO2012042128A1 (fr) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
IL110309A0 (en) * | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
-
2010
- 2010-09-29 FR FR1003859A patent/FR2965178B1/fr active Active
-
2011
- 2011-09-27 WO PCT/FR2011/000528 patent/WO2012042128A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
FR2965178A1 (fr) | 2012-03-30 |
WO2012042128A1 (fr) | 2012-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL237369A0 (en) | Methods for treating Alzheimer's disease and pharmaceutical compositions thereof | |
BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
JP2015501783A5 (fr) | ||
EP2151435A4 (fr) | Composition pharmaceutique pour le traitement de la maladie d'alzheimer | |
CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
BR112015000150A2 (pt) | composições farmacêuticas dissuasoras de abuso de liberação controlada | |
EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
DK2276485T3 (da) | Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom | |
CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
SG10201704712QA (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
EP2568811A4 (fr) | Traitement du tcl et de la maladie d'alzheimer | |
MA40846A (fr) | Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques | |
EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
FR2934267B1 (fr) | Derives aminophosphiniques utiles dans le traitement de la douleur | |
DE102009018133A8 (de) | Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen | |
EA201690659A1 (ru) | Композиции аморфного магнийзамещенного фосфата кальция и их применение | |
IL237730B (en) | Treatment of mild and moderate Alzheimer's disease | |
FR2918282B1 (fr) | Medicament pour le traitement de la maladie de parkinson | |
CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
FR2993564B1 (fr) | Derives d'imidazopyridine utiles dans le traitement du diabete | |
PT2603238E (pt) | Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo | |
FR2963237B1 (fr) | Nouvelle composition pharmaceutique utile pour prevenir ou traiter l'hypotension arterielle peroperatoire chez l'etre humain | |
FR2965178B1 (fr) | Composition pharmaceutique utilise dans le traitement de la maladie d'alzheimer | |
FR2953723B1 (fr) | Composition pharmaceutique destinee au traitement des pathologies orthopediques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 8 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
PLFP | Fee payment |
Year of fee payment: 10 |
|
PLFP | Fee payment |
Year of fee payment: 11 |
|
PLFP | Fee payment |
Year of fee payment: 12 |
|
PLFP | Fee payment |
Year of fee payment: 13 |
|
PLFP | Fee payment |
Year of fee payment: 14 |